Ascletis pharma says unit & galmed pharmaceuticals entered research agreement

Unit and galmed pharmaceuticals entered research agreement aiming at combination therapy of asc41 and aramchol.agreement aiming at combination therapy of asc41 and aramchol for treatment of non-alcoholic steatohepatitis.

GLMD Ratings Summary

GLMD Quant Ranking